An innovative new blood test can detect breast cancer up to 5 years before symptoms appear, researchers say. Developed by a team at the University of Nottingham, England, the new blood test identifies specific immune system ‘autoantibodies’, which are produced when tumor-associated antigens (TAAs) are present – like those produced by breast cancer cells. While the test is still only partially effective, it could eventually provide the best chance of detecting breast cancer early, enabling faster treatment and a greater chance of success. In the pilot study, the researchers took blood samples from 90 breast cancer patients when they were diagnosed with breast cancer. They then matched these samples with ones from 90 patients without breast cancer. Then, they used a technology called protein microarray to test the blood samples for the presence of autoantibodies and 40 TAAs associated with breast cancer, plus another 27 TAAs that were not known to be linked with the disease). The researchers used a technology called protein microarray to rapidly test the blood samples for autoantibodies against 40 TAAs associated with breast cancer, plus another 27 TAAs that were not known to be linked with the disease. Speaking last Sunday at the U.K. National Cancer Research Institute conference in Glasgow, Scotland, researcher Daniyah Alfattani, a Ph.D. student at the University of Nottingham's Centre of Excellence for Autoimmunity in Cancer (CEAC), said: “The results of our study showed that breast cancer does induce autoantibodies against panels of specific tumor-associated antigens. We were able to detect cancer with reasonable accuracy by identifying these autoantibodies in the blood.” At present, annual mammograms are the best way for doctors to detect the presence of breast cancer while in its early stages.